Surface Logix CEO Resigns

Surface Logix CEO Resigns

BOSTON, May 15 -- Surface Logix today announced that Jim Mahoney, President & CEO, will be stepping down from his current position to pursue other interests. Mr. Mahoney will maintain a consulting relationship with the company for the foreseeable future. Steven Gillis, Ph.D., Managing Director at ARCH Venture Partners will assume the role of Executive Chairman until a new CEO is appointed.

"The Board, shareholders and employees of Surface Logix would like to thank Jim for his considerable contributions to the Company. He led the transformation of Surface Logix from a chemistry platform to a small molecule drug discovery and development company with two internally generated programs having completed several successful Phase 2a clinical trials. Everyone at Surface Logix wishes Jim well in his decision to pursue other interests," said Steven Gillis. "Surface Logix is well positioned to move forward both of our cardiovascular programs, SLx-4090 and SLx-2101, into Phase 2b studies. Both programs have demonstrated clear efficacy and excellent tolerability and safety in clinical trials to date. We will also continue our research activities aimed at bringing exciting new programs to the clinic."

About Surface Logix, Inc.

Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior drug-like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, oncologic and fibrotic diseases. For more information, please visit http://www.surfacelogix.com .

Contact: Leland Webster, Ph.D., M.B.A. Surface Logix, Inc. Vice President, Corporate Development 617.746.852

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.